Renal Handling of Free and Acylcarnitine in Secondary Carnitine Deficiency
Authors
Affiliations
Free and acylcarnitine in serum and urine samples were measured in miscellaneous diseases, including mitochondrial cytopathy with Fanconi's syndrome (MCFS). The urinary concentration of acylcarnitine always exceeded that of free carnitine, and a significant negative correlation was found between the ratio of serum free to acylcarnitine and the ratio of free to acylcarnitine clearance among control and test patients (p less than 0.005). A patient with MCFS excreted large amounts of free carnitine compared with acylcarnitine in urine, which may be attributable to decreased reabsorption of free carnitine in renal tubules.
Ito M, Fukuda M, Suzuki Y, Wakamoto H, Ishii E BMC Pediatr. 2017; 17(1):73.
PMID: 28292283 PMC: 5351108. DOI: 10.1186/s12887-017-0835-7.
Uptake carriers and oncology drug safety.
Sprowl J, Sparreboom A Drug Metab Dispos. 2014; 42(4):611-22.
PMID: 24378324 PMC: 3965905. DOI: 10.1124/dmd.113.055806.
Inhibition of OCTN2-mediated transport of carnitine by etoposide.
Hu C, Lancaster C, Zuo Z, Hu S, Chen Z, Rubnitz J Mol Cancer Ther. 2012; 11(4):921-9.
PMID: 22389472 PMC: 3466062. DOI: 10.1158/1535-7163.MCT-11-0980.
Cisplatin-induced downregulation of OCTN2 affects carnitine wasting.
Lancaster C, Hu C, Franke R, Filipski K, Orwick S, Chen Z Clin Cancer Res. 2010; 16(19):4789-99.
PMID: 20858838 PMC: 3531239. DOI: 10.1158/1078-0432.CCR-10-1239.
Pharmacokinetics of L-carnitine.
Evans A, Fornasini G Clin Pharmacokinet. 2003; 42(11):941-67.
PMID: 12908852 DOI: 10.2165/00003088-200342110-00002.